shine-logo

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

2022-02-09T20:42:58-06:00February 10, 2022|2022, News, News Releases|

SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands

A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.

2022-02-01T17:57:14-06:00February 2, 2022|2022, News, News Releases|

SHINE Medical Technologies Closes $150-million Series C-5 Financing

SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.

2021-12-17T17:35:59-06:00June 28, 2021|2021, News, News Releases|

SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries

2021-12-17T17:36:27-06:00May 25, 2021|2021, Medical Isotopes, News, News Releases, Therapeutics|

SHINE, Phoenix merger focused on advancing fusion technology 

JANESVILLE and FITCHBURG, Wis., April 20, 2021 – SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.

2021-12-17T17:37:03-06:00April 20, 2021|2021, News, News Releases, Nuclear Fusion|

SHINE breaks ground on HQ and Therapeutics production facility

SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.

2021-12-17T17:38:43-06:00December 16, 2020|2020, News, News Releases, Therapeutics|

SHINE announces first sales of n.c.a. Lu-177

SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.

2021-12-17T17:38:58-06:00November 4, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|

SHINE closes $80-million

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.

2021-12-16T20:07:17-06:00September 3, 2020|2020, News, News Releases|

SHINE & IOCB deliver Lu-177 doses to GE

SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).

2021-12-16T20:07:30-06:00January 21, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|
Go to Top